Slide 1: Q3 2025 Financial Results
Q3 2025 Financial Results Conference call | October 28, 2025 www.materialise.com | NASDAQ: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentatio n conta ins forwa rd-looking statements within the meaning of Sectio n 27A of the Securities Act of 1933, as amended, and Sectio n 21E of the Securities Excha nge Act of 1934, as amended, regar ding, among other things, our intentio ns, beliefs, assumptions, proj
Slide 3: Agenda
Agenda • Q3 2025 Business Highlights Brigitte de Vet-Veithen • Q3 2025 Financial Highlights CEO • Q3 2025 Financial Results • 2025 Financial Guidance Update • Q&A Koen Berges CFO 3
Slide 4: Q3 2025 - Business Highlights
Q3 2025 - Business Highlights Medical: Scaling up to reach more patients • Next steps in cardiac with extended planning solutions and clinical evidence • Release of Mimics Enlight CMF 7.0 for reconstruction and trauma Software: Progress to establish CO-AM as the ecosystem for all AM operations • Pow
Slide 5: Q3 2025 – Financial Highlights
Q3 2025 – Financial Highlights • Revenue of 66.3 mEUR, representing a decrease of 3.5% from a strong Q3 2024 • Gross Profit of 37.7 mEUR, representing 56.8% of revenue • Adjusted EBIT of 2.9 mEUR, representing 4.4% of revenue • Net profit of 1.8 mEUR, representing 3 EUR-ct. per share • Reported Net
Slide 6: Consolidated Revenue
Q3 2025 Consolidated Revenue Q3 2025 Revenue by Segment -3.5% 68,652 Software 66,259 16% Medical 34% Manufacturing 50% Q3 2024 Q3 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Revenue of 66.3 mEUR, representing a decrease of 3.5% compared to Q3 2024 but up 2.2% ve
Slide 7: Consolidated Adjusted EBIT & EBITDA
Q3 2025 Consolidated Adjusted EBIT & EBITDA -14.8% 4,408 -33.8% 9,895 8,428 14.4% 6.4% 2,918 12.7% 4.4% Q3 2024 Adj. EBIT Q3 2025 Q3 2024 Adj. EBITDA Q3 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q3 2025 Adjusted EBIT decreased by 34% to 2.9 mEUR compared to Q3
Slide 8: Medical Segment
Q3 2025 Medical Segment +10.3% +3.1% 33,296 9,895 10,199 30,197 30.6% 32.8% Q3 2024 Revenue Q3 2025 Q3 2024 Adj. EBITDA Q3 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q3 2025 revenue increased 10.3% to 33.3 mEUR compared to Q3 2024 • Revenue from medical softwar
Slide 9: Software Segment
Q3 2025 Software Segment -7.4% -8.8% 11,111 1,975 10,286 1,801 17.8% 17.5% Q3 2024 Revenue Q3 2025 Q3 2024 Adj. EBITDA Q3 2025 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Q3 2025 revenue decreased by 7% to 10.3 mEUR compared to Q3 2024 partly due to unfavorable forex
Slide 10: Manufacturing Segment
Q3 2025 Manufacturing Segment -17.1% 27,344 701 22,677 2.6% -3.7% Q3 2024 Revenue Q3 2025 (845) Adj. EBITDA [Data in kEUR unless notes otherwise. All numbers and percentages rounded] Q3 2024 Q3 2025 • Segment revenue decreased by 17% to 22.7 mEUR compared to Q3 2024 • Growth in certified manufacturi
Slide 11: Income Statement Highlights
Income Statement Highlights Q3 2025 Q3 2024 Gross profit margin (in %) Revenue 66,259 68,652 57.2% 56.8% Cost of sales (28,608) (29,355) Gross profit 37,651 39,297 Research & development expenses (11,439) (10,979) Sales & marketing expenses (14,847) (14,896) Q3 2024 Q3 2025 General & administrative
Slide 12: Other Financial Highlights
Other Financial Highlights Balance Sheet items 09/30/25 12/31/24 Cash flow from operations 10,359 Cash and equivalents 132,022 102,304 6,870 Borrowings 64,278 41,284 Net Cash 67,744 61,020 Q3 2024 Q3 2025 Trade receivables 44,894 53,052 Inventories 15,678 16,992 Capital expenditures (cash impact) Tr
Slide 13: 2025 Financial Guidance Update
2025 Financial Guidance Update Maintaining prior guidance on revenue and Adjusted EBIT • Expect 2025 consolidated revenue within 265 - 280 mEUR range • Expect 2025 consolidated Adjusted EBIT within 6 - 10 mEUR range 13
Slide 14: Adjusted EBIT/Adjusted EBITDA Reconciliation
Appendix Adjusted EBIT/Adjusted EBITDA Reconciliation [Data in kEUR unless noted otherwise. All numbers and percentages rounded] Q3 2025 Q3 2024 Net profit/(loss) 1,848 3,038 Income taxes 553 138 Financial expenses 582 1,843 Financial income (460) (706) EBIT 2,522 4,313 Depreciation & amortization 5
Slide 15: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 15